i&i Biotech Fund

Antiverse is an innovative biotechnology company specializing in accelerating drug development through its proprietary platform. This platform combines structural biology, machine learning, and medicine to facilitate quicker and more cost-effective breakthroughs in antibody discovery.

Captain T Cell is a biotechnology company focused on developing innovative T cell-based immunotherapies for cancer patients. It specializes in identifying novel high-efficiency TCRs and advancing them through CMC and preclinical development for its lead candidates.

Casinvent Pharma develops therapeutic compounds targeting selected malignancies. It focuses on using proprietary selective inhibitors of enzymes from the CK1 family to prevent leukemia cell migration into lymphoid organs.

HeartBeat.bio develops therapies for heart failure and related cardiomyopathies using a human-centric drug discovery platform. It operates a high-throughput 3D screening system and creates iPSC-derived multicellular, lineage-controlled cardiac tissue models from healthy donors and patients that recapitulate the physiology of the human heart. These models enable more accurate evaluation of drug candidates and aim to improve translation to clinical outcomes in cardiovascular research.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in the commercialization of advanced biosensor technology. The company focuses on developing photonic biosensors that integrate optical chips with waveguides to facilitate multiplexed biosensing. This technology enables real-time monitoring through highly sensitive refractive index sensors, allowing for label-free biosensing. Delta Diagnostics aims to provide rapid, sensitive, and cost-effective solutions that can significantly enhance research in the Life Sciences sector. By enabling accurate measurement of multiple biomarkers within minutes, the company aspires to drive new discoveries and foster the development of innovative diagnostics.

Sophomer is a company that specializes in developing synthetic polymers intended to replace bovine serum albumin in immunological tests. By integrating the fields of immunoassays and polymer chemistry, Sophomer offers innovative solutions for immunochemical assays, enhancing the accuracy and efficiency of these diagnostic tools. The company's focus on artificial polymers aims to improve the quality of testing while addressing the limitations associated with traditional protein-based reagents.

Enzyre develops point-of-care diagnostic technology designed to bring lab testing capabilities to patients' homes or healthcare settings. Their device focuses on blood coagulation, measuring up to twelve reactions using a small volume of blood, improving patient quality of life without increasing healthcare costs.

Nanoligent is a biotech company that originated as a spin-off from Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. The company focuses on the design and development of targeted therapeutic biologics, particularly in the realm of nanotechnology-based anti-cancer treatments. Utilizing advanced protein engineering and nanobiotechnology, Nanoligent creates self-assembling protein nanoparticles that selectively target and kill metastatic cancer cells. This innovative approach aims to enhance treatment effectiveness while minimizing adverse effects, ultimately striving to improve patient outcomes by developing medicines that directly address the cells affected by disease.

Casinvent Pharma develops therapeutic compounds targeting selected malignancies. It focuses on using proprietary selective inhibitors of enzymes from the CK1 family to prevent leukemia cell migration into lymphoid organs.

Sampling Human develops computational products to measure and analyze single-cell and spatial omic data at an industrial scale. Its technology enables pre-symptomatic screening, personalized medicine, drug discovery, and advancements in basic science.